Look at the company leadership structure.
Cnbx are licensed by the Ministry of Health. Extensive IP value. With well connected leadership in government.
My DD…..also points to a Big Pharma BO imo only. So everyone should do their own DD.
LEADERSHIP
“Our company's Leadership is comprised of our Board of Directors, responsible for strategy and direction, our Management, responsible for execution and administration, and our Advisory Board that provides us with invaluable input and advise.“……….
BOARD OF DIRECTORS
GABRIEL YARIV..
Mr. Yariv, 44, brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the founding group of breathID an Oridion Medical (now Medtronic) business unit and subsequent spin off company BreathID Inc. (now Exalenz Bioscience) which develops and manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv also co-founded and was CEO of Simutec, a medical simulation and training company that develops and commercializes advanced personalized virtual reality training programs for physicians, Hospitals, Private and Governmental Healthcare Organizations.
Prior to his nomination as Chairman of the corporation, Mr. Yariv served as President & COO of Cannabics Pharmaceuticals.
Mr. Yariv is actively engaged in non-profit and philanthropic activities including ongoing business mentoring of entrepreneurs, founder and CEO of the Yariv Foundation for Leadership, and current member of the Friends of the Israel Museum Society.
Mr. Yariv holds a BA Cum Laude from Boston University in Philosophy, Political Science and History.
DR. INBAR MAYMON-POMERANCHIK….
Dr. Maymon-Pomeranchik, 43, is trained as a molecular and genetic researcher holding a PhD from the Hebrew University, and brings nearly 20 years of executive level experience in biotech sciences, with particular expertise in the global medical cannabis industry. Dr. Maymon-Pomeranchik also serves on the boards of several public companies.
Dr. Maymon-Pomeranchik is the founder & CEO of AgChimedes Group Ltd., a company focused on the convergence of science, innovation and investment in the field of food security; she also founded BioDiligence, a biotech investment consultancy; Executive Director of Ananda Developments Pls (UK), an investment and operational firm that targets medicinal cannabis derivatives for research and development; a Director of NRGene (Israel), a company that develops and commercializes cutting-edge AI based genomic tools, and an Advisory Board member of Avida Global Ltd. (UK/Columbia), Avida is a leading licensed producer of pharmaceutical grade cannabis extract for scientific and medical use. Dr. Maymon-Pomeranchik holds a PhD in plants science and molecular biology from the Hebrew University (2008) and a Post Doctorate from the Weizmann Institute (2010).
DR. GIL FEILER
About Dr. Gil Feiler:……
During 20 years in academia, Dr. Feiler taught Business, Economics, and Middle East Studies as an Associate Professor at Tel Aviv University, Bar Ilan University and at the Interdisciplinary Center Herzlia. He has extensive senior executive business experience in both small and large companies, including Coca Cola Israel; he is founder of the largest news portal in the Arabic world, and has served on the board of The First International Bank of Israel, Mutual Fund Division; Dr. Feiler also served as Special Business Advisor to the Government of Ras al-Khemah, United Arab Emirates.
DR. FEILER IS AN ALUMNI OF THE US STATE DEPARTMENT INTERNATIONAL VISITOR LEADERSHIP PROGRAM (1997), AND HAS ALSO PUBLISHED EXTENSIVELY ON BUSINESS OPPORTUNITIES IN THE MIDDLE EAST, ON POLITICAL ECONOMY, ON ECONOMIC COOPERATION, AND ON FINANCING OF TERRORISM. HE IS ALSO THE AUTHOR OF SEVERAL BOOKS INCLUDING: RETHINKING BUSINESS STRATEGY FOR THE MIDDLE EAST AND NORTH AFRICA (LONDON: THE ECONOMIST, 1997); FROM BOYCOTT TO ECONOMIC COOPERATION: AN ANALYSIS OF THE ARAB BOYCOTT OF ISRAEL (LONDON: FRANK CASS: 1998), THE MIDDLE EAST IN THE NEW MILLENNIUM (NEW YORK: KLUWER LAW INTERNATIONAL, 2000), ECONOMIC RELATIONS BETWEEN EGYPT AND THE GULF OIL STATES: PETRO-WEALTH AND PATTERNS OF INFLUENCE (BRIGHTON: SUSSEX ACADEMIC PRESS, 2003), AND INVESTING IN RUSSIA, THE UKRAINE, LATVIA, LITHUANIA AND KAZAKHSTAN (PORTLAND: SUSSEX ACADEMIC PRESS, 2007) (CO-AUTHORED WITH ALEXANDRE GARESE).
Dr. Feiler delivered papers at the UN, at Harvard conferences and at the World Economic Forum in Davos.
SHAUL YEMAL……
Mr. Yemal serves as a director of CNBX Pharma since 2021; he is also member of the Company’s Compensation and Nomination & Governance Committees, as well as Head of the Company’s Audit Committee. From 2012 to 2020, Mr. Yemal served as a director and Chairman of the Audit Committee at Medtechnica Ltd., a sales and marketing company focused in medical equipment. Mr. Yemal has also served as Senior Economist in the Division of Economic Consulting for the Ministry of Finance, Budget Division of the Minister of Finance and Manager of the Economic and Planning Division of the Ministry of Energy (Israel). Mr. Yemal served as Chief Executive Officer of ICL in Santiago, Chile, Senior VP of Business Development for ISAL Amlat VC Fund; Senior VP Corporate Manager and Board Member of Oridion Medical,. Mr. Yemal holds a Masters Degree in Economics from the University of Rosario, Argentina. We believe Mr. Yemal is qualified to serve as a member of our board of directors because of his extensive executive and business experience in relevant industries.
EYAL BARAD…..
Mr. Barad serves also as CEO of Cannabics Pharmaceuticals. See Mr. Barad’s bio bellow under “Management”
News 
Market Data 
Discover 
